<DOC>
	<DOCNO>NCT02067832</DOCNO>
	<brief_summary>Chronic graft-versus-host disease ( cGVHD ) hard diagnose , difficult manage contribute significantly morbidity mortality stem cell transplantation patient . The research look identify validate cGVHD biological indicator ( =bio-markers ) evaluate whether predict future development disease . The study hypothesis number previously report cGVHD bio-markers , know present time cGVHD diagnosis , also present early time point , cGVHD develops . Following validation , bio-markers beneficial finding patient higher risk develop cGVHD . By identify higher-risk group , likely develop cGVHD , pre-emptive therapy might apply order prevent reduce prevalence disease .</brief_summary>
	<brief_title>Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>1 . Allogeneic hematopoietic stem cell transplantation malignant nonmalignant disease . 2 . Age 017.99 year time transplantation . 3 . Bone marrow , peripheral blood stem cell umbilical cord blood ( include single double cord blood ) graft source . 4 . Any condition regimen chemotherapy / radiation therapy combination . Haploidentical donor transplant posttransplant cyclophosphamide also allow . 5 . Use serotherapy permit . 6 . Any graftversushost disease prophylaxis permit , include postHSCT cyclophosphamide . 7 . If participant weigh 020 kg , participant must able provide 15 ml whole blood time point . 8 . If participant weigh 20 kg , participant must able provide 1ml/kg whole blood , maximum 23 mL precondition sample 32 mL sample day +100 , 6months , 12months , +/ cGVHD sample . 9 . Written inform consent parent . 10 . Assent study participant appropriate . 11 . Participation clinical trial acceptable . 1 . Autologous HSCT . 2 . Patients refer Bone Marrow Transplant ( BMT ) center nonBMT center , anticipate ( discretion center PI ) adequate follow accord rule protocol meet , include requirement reassessment BMT center time cGVHD diagnosis . 3 . Exvivo Tcell depletion graft source ( e.g . CD34 selection ) . 4 . Second ( great ) allogeneic transplant ( first allogeneic transplant previous autologous transplant perform permit ) . 5 . Syngeneic transplant .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>